Title : Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.

Pub. Date : 2021 Jun 25

PMID : 33981831






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab"s antibody-dependent cellular cytotoxicity (ADCC) efficacy. ibrutinib IL2 inducible T cell kinase Homo sapiens
2 However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab"s antibody-dependent cellular cytotoxicity (ADCC) efficacy. ibrutinib IL2 inducible T cell kinase Homo sapiens